Chesapeake Capital Corp IL Takes $148,000 Position in Grifols, S.A. (NASDAQ:GRFS)

Chesapeake Capital Corp IL acquired a new stake in shares of Grifols, S.A. (NASDAQ:GRFS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 16,500 shares of the biotechnology company’s stock, valued at approximately $148,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the last quarter. Signaturefd LLC grew its stake in shares of Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Grifols in the second quarter worth about $89,000. Cetera Advisors LLC bought a new stake in shares of Grifols in the first quarter worth about $147,000. Finally, Creative Planning grew its stake in shares of Grifols by 26.4% in the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 3,614 shares during the last quarter.

Grifols Stock Down 0.8 %

NASDAQ GRFS opened at $9.47 on Monday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The business’s 50-day moving average is $8.87 and its 200 day moving average is $8.01.

Analyst Ratings Changes

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.